Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175510 | 0.81 | CA1 (0.36) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL5320893 | 0.79 | CA1 (0.35) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL24049964 | 0.79 | KDM4E (0.49) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL5347897 | 0.79 | CA1 (0.36) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL31319651 | 0.77 | GABRA5 (0.36) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL29953477 | 0.77 | CA1 (0.33) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL16245642 | 0.73 | CA1 (0.35) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL10298270 | 0.71 | ATR (0.46) | CA1CA2CA12CA9CYP17A1 | |
| SCHEMBL24049966 | 0.71 | AAK1 (0.36) | CA1CA2CA12CA9PSMB8 | |
| SCHEMBL27042890 | 0.71 | CYP17A1 (0.34) | CA1CA2CA12CA9CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | PALAU PHARMA, S.A. (ES) | 2008-12-25 | — | — | US | disclosed |
| EP-1833828-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | Palau Pharma, S.A. (ES) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006013095-A2 | CONDENSED PYRIDINES AS KINASE INHIBITORS | PALAU PHARMA, S.A. (ES) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264446-A9 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | CA1 3352/4885CA2 2864/4885CA12 4806/4885 |
| US-20080318977-A1 | Condensed Pyridines as Kinase Inhibitors | MAPK1, MAP4K2, MAP3K1 | CA1 3352/4885CA2 2864/4885CA12 4806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.